How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Non-GLP Acute Toxicology Market
- By Study Type: Single Dose Toxicity, Repeated Dose Toxicity, Neurotoxicity Studies, Dermal Toxicity, Inhalation Toxicity
- By Test Substance: Pharmaceutical Compounds, Industrial Chemicals, Pesticides, Cosmetic Ingredients, Food Additives
- By Test System: Rodent Models, Non-Rodent Mammals, In Vitro Cell Cultures, Alternative Models (e.g., Zebrafish)
- By Endpoint Measured: Mortality, Clinical Signs, Body Weight Changes, Histopathology, Biochemical Parameters
- By Service Provider Type: Contract Research Organizations (CROs), In-House R&D Laboratories, Academic Research Institutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Single Dose Toxicity leads By Study Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.181 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.189 →
Full report · locked preview
Everything inside the Non-GLP Acute Toxicology Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Study Type 5
Test Substance 5
Test System 4
Endpoint Measured 5
Service Provider Type 3
Companies profiled
Charles River Laboratories
Covance (Labcorp Drug Development)
Eurofins Scientific
Envigo
WuXi AppTec
Pace Analytical Services
QPS Holdings
Toxikon Corporation
MPI Research (now part of Charles River)
BioReliance (a Merck KGaA company)
NAMSA
Frontage Laboratories
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Covance (Labcorp Drug Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Envigo
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →WuXi AppTec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pace Analytical Services
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →QPS Holdings
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Toxikon Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MPI Research (now part of Charles River)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BioReliance (a Merck KGaA company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →NAMSA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Frontage Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Vivotecnia
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Bioneeds India
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Accutox
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,757M by 2033 · 10.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Single Dose Toxicity52.9
- Repeated Dose Toxicity8.1
- Neurotoxicity Studies7.9
- Dermal Toxicity16.1
- Inhalation Toxicity14.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,750M → $4,298M · 11.9%
Europe$1,220M → $2,466M · 9.2%
Asia Pacific$1,114M → $2,602M · 11.2%
Latin America$689.5M → $1,542M · 10.6%
Middle East and Africa$530.3M → $1,254M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.412026
10.422027
10.452028
10.452029
10.472030
10.472031
10.482032
10.502033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories29.9
- Covance (Labcorp Drug Development)11.4
- Eurofins Scientific4.2
- Envigo13.9
- WuXi AppTec5.8
- Pace Analytical Services6.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Study Type16.1%
Test Substance25.1%
Test System27.1%
Endpoint Measured11.1%
Service Provider Type20.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.3
- Europe20.3
- Asia Pacific21.4
- Latin America12.7
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories | 94 | 82 | 87 | 75 | 92 | 82 | 85 |
| Covance (Labcorp Drug Development) | 89 | 91 | 68 | 80 | 93 | 91 | 85 |
| Eurofins Scientific | 67 | 84 | 72 | 84 | 79 | 71 | 76 |
| Envigo | 59 | 80 | 61 | 67 | 59 | 77 | 67 |
| WuXi AppTec | 54 | 73 | 53 | 61 | 67 | 56 | 61 |
| Pace Analytical Services | 47 | 67 | 64 | 49 | 71 | 59 | 60 |
| QPS Holdings | 41 | 47 | 57 | 65 | 40 | 44 | 49 |
| Toxikon Corporation | 36 | 60 | 45 | 48 | 58 | 60 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories
- Covance (Labcorp Drug Development)
- Eurofins Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Covance (Labcorp Drug Development) | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Eurofins Scientific | ◐ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Envigo | ◐ | ◐ | − | ✓ | − | ◐ |
| WuXi AppTec | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| Pace Analytical Services | − | ◐ | ✓ | − | ◐ | − |
| QPS Holdings | − | − | − | − | − | − |
| Toxikon Corporation | − | − | − | ◐ | − | ✓ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories85
2Covance (Labcorp Drug Development)85
3Eurofins Scientific76
4Envigo67
5WuXi AppTec61
6Pace Analytical Services60
7Toxikon Corporation51
8QPS Holdings49
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Charles River LaboratoriesCovance (Labcorp Drug Development)
Challenger2
Strong scale, closing on the leaders.
Eurofins ScientificEnvigo
Contender2
Focused players with pockets of strength.
WuXi AppTecPace Analytical Services
Niche2
Specialists in a single segment or region.
QPS HoldingsToxikon Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Study Type in North America, then scale across Non-GLP Acute Toxicology Market — a $446M beachhead inside a $6.65B market.
Beachhead (SOM)$446Mobtainable near-term
Serviceable (SAM)$2.65Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Single Dose Toxicity
Best fit — highest urgency & budget in Study Type.
Economic buyer80 fit
Repeated Dose Toxicity
Strong fit — clear ROI and a fast path to value.
End user66 fit
Neurotoxicity Studies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Study Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Test Substance & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Test System
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Study Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Non-GLP Acute Toxicology Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation12%
Closed-won7%
$18.0KCAC
$61KLTV
3.4:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Non-GLP Acute Toxicology Market is a high-growth opportunity — $3.34B by 2033, compounding at 11.1%.
TAM · 2025$1.44Btoday
TAM · 2033$3.34Bforecast
CAGR11.1%2027–2033
Cumulative$20.5Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.34BTotal addressable market
SAM$1.31BServiceable available market
SOM$288MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.1% CAGR
Demand compounds through 2033, outpacing GDP across Study Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Study Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.34BLarge & growingTAM by 2033 at 11.1% CAGR
$1.31BServiceable nowreachable with today’s model
$288MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.61BBear7.2% CAGR
$3.34BBase11.1% CAGR
$4.28BBull14.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Test Substance optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Non-GLP Acute Toxicology Market — a $3.53B market by 2033. Plan: grow share from 6.4% to 13.2%.
Market size · 2033$3.53Btotal addressable
Market CAGR6.5%2027–2033
Target share13.2%from 6.4% today
Revenue ambition$466Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.4% | 13.2% | Behind |
| Revenue | $236M | $466M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 33.7% | 43.1% | On track |
| Customer retention | 88.7% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Study Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Test Substance capability
A defensible second engine — invest in Test Substance to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Study Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Test Substance
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $53M capacity & capability investment
- Greenlight bolt-on M&A in Test Substance
- Authorise North America expansion plan
- Fund R&D program for Study Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Non-GLP Acute Toxicology Market conversation — a $2.93B market you can size, segment and defend in minutes.
Market size · 2033$2.93Btotal opportunity
Growth9.8%CAGR to 2033
Addressable buyers1,437+accounts in scope
Typical ROI4.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Study Type
Goal Grow share in Study Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.6×return on cost, year one
< 3 mopayback period
$42K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Charles River LaboratoriesCovance (Labcorp Drug Development)Eurofins ScientificEnvigoWuXi AppTecPace Analytical ServicesQPS HoldingsToxikon Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Non-GLP Acute Toxicology Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Non-GLP Acute Toxicology Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Non-foldable Intraocular Lens Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportNon-flexible Paper Pipet Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportNon-Filtered Pipette Tips Market
Market size, share, segmentation and regional forecast.
$348M market · 2025 base year
View reportNonerosive Reflux Disease Treatment Market
Market size, share, segmentation and regional forecast.
$928M market · 2025 base year
View reportNon-emergency Patient Transfer Services Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportNon-emergency Medical Transport (NEMT) Service Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportNon-Emergency Medical Transportation Service Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportNon-Emergency Medical Transportation Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportNo Needle Mesotherapy Machine Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportNon-dialysis Medical Packaging Base Paper Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportNon-Destructive Medical Device Market
Market size, share, segmentation and regional forecast.
$762M market · 2025 base year
View reportNon-crosslinked Hyaluronic Acid Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.